TB Alliance Statement on WHO’s Global Tuberculosis Report 2017
The World Health Organization’s (WHO) 2017 Global Tuberculosis Report, released today, showed a reduction in TB deaths in 2016 compared
TB Alliance Moves Two Novel Tuberculosis Drugs into Human Trials
GUADALAJARA (10 October, 2017) — TBA-7371 and sutezolid entered phase 1 clinical trials, TB Alliance announced today. Both compounds have
TB Alliance Endorses WHO Designation of TB as a “Global Priority Pathogen”
NEW YORK (27 September, 2017)—TB Alliance commends the World Health Organization (WHO) for recognizing tuberculosis (TB) as a priority pathogen
WHO Prequalifies Childhood TB Medicine
The World Health Organization (WHO) has just prequalified a two-pills-in-one pediatric medicine that is critical for the continuation phase of
TB Alliance applauds G20 Communiqué
HAMBURG, July 10 2017 – TB Alliance joins a coalition of 35 worldwide health advocates as well as numerous individuals from research institutes,
An Open Letter to Dr. Tedros
On May 23, 2017, the World Health Assembly elected Dr. Tedros Adhanom Ghebreyesus as the next Director-General of the World Health Organization.
EU Leaders Urge Funding of Critically-needed New Tools against Drug-resistant Tuberculosis
BRUSSELS, 11 MAY 2017 — Leaders from the governments of France and the Netherlands today urged funding for new treatment
TB Alliance Sublicenses Promising Anti-Tuberculosis Drug from the Medicines Patent Pool
NEW YORK and GENEVA, 24 March 2017 — On World Tuberculosis Day, TB Alliance and the Medicines Patent Pool (MPP)
TB Alliance Calls on WHO to Add TB to List of Bacteria in Critical Need of Antibiotics
TB Alliance and the broader TB community urge that the World Health Organization (WHO) add Mycobacterium tuberculosis to the critical
Médecins Sans Frontières Partners with TB Alliance in Three-Country Study
TB Alliance will provide pretomanid, a drug in the final stages of clinical development, as well as its drug development